AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a study titled ‘A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE).’ The study aims to evaluate the safety, tolerability, and efficacy of AZD0120 in adults with refractory SLE, a challenging autoimmune condition.
The intervention being tested is AZD0120, a dual CAR T cell therapy designed to target CD19 and BCMA. This biological treatment is intended to improve outcomes for patients with refractory SLE by modulating immune responses.
This interventional study is structured in two sequential phases: Phase 1b focuses on assessing safety and tolerability, while Phase 2 evaluates the efficacy of the selected dose. The study is open-label, meaning both researchers and participants know the treatment being administered, and it primarily aims to treat refractory SLE.
The study began on April 21, 2025, with its primary completion and estimated overall completion dates yet to be announced. The last update was submitted on July 15, 2025, indicating ongoing recruitment and progress.
The market implications of this study are significant for AstraZeneca, as successful results could enhance its portfolio in the autoimmune disease sector, potentially boosting stock performance and investor confidence. The study’s progress is particularly relevant in the context of increasing competition in CAR T cell therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.